Nationwide Shortage of Albuterol Inhalers and Off-Label Use in COVID-19 Patients

被引：5
|
作者：
Hendeles, Leslie [1 ,2 ]
Prabhakaran, Sreekala [2 ]
机构：
[1] Univ Florida, Coll Pharm, Gainesville, FL USA
[2] Univ Florida, Dept Pediat, Gainesville, FL USA
来源：
PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY | 2020年 / 33卷 / 04期
关键词：
albuterol; COVID-19; HFA MDI; drug shortages;
D O I：
10.1089/ped.2020.1300
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
The surge in COVID-19 cases during the 2020 Spring led to a nationwide shortage of albuterol inhalers. As a new surge has begun, shortages may make it difficult for patients with obstructive lung disease, including children with asthma, to obtain refills. Since there is no evidence that albuterol relieves symptoms in COVID-19 patients with respiratory symptoms not caused by bronchospasm, it is reasonable for clinicians to not prescribe it for COVID-19 patients unless they also have asthma or chronic obstructive pulmonary disease.
引用
收藏
页码：216 / 219
页数：4
相关论文
共 50 条
  • [41] ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic
    Stolbach, Andrew, I
    Mazer-Amirshahi, Maryann
    Marino, Ryan
    Nelson, Lewis S.
    Sugarman, Jeremy
    JOURNAL OF MEDICAL TOXICOLOGY, 2020, 16 (03) : 342 - 345
  • [42] COVID-19 off-label uses of medicines: the role of civil liability and regulation
    Andrea Parziale
    The Geneva Papers on Risk and Insurance - Issues and Practice, 2023, 48 : 669 - 686
  • [43] ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic
    Andrew I. Stolbach
    Maryann Mazer-Amirshahi
    Ryan Marino
    Lewis S. Nelson
    Jeremy Sugarman
    Journal of Medical Toxicology, 2020, 16 : 342 - 345
  • [44] Pediatric Off-Label COVID-19 Vaccination: The Concerns of Healthcare Professionals in Pakistan
    Shakeel, Sadia
    Nesar, Shagufta
    Nizami, Ghazala Noor
    Iqbal, Zafar
    Emad, Shaista
    Wasim, Quratulain
    Mumtaz, Tayyaba
    Jamshed, Shazia
    Usmani, Muhammad Salahuddin
    Hussain, Rabia
    VACCINES, 2022, 10 (08)
  • [45] Antibacterials/antivirals/immunosuppressantsCOVID-19 infection, COVID-19 pneumonia and off-label use: 7 case reports
    Reactions Weekly, 2022, 1889 (1) : 38 - 38
  • [46] Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19
    Sciascia, S.
    Apra, F.
    Baffa, A.
    Baldovino, S.
    Boaro, D.
    Boero, R.
    Bonora, S.
    Calcagno, A.
    Cecchi, I.
    Cinnirella, G.
    Converso, M.
    Cozzi, M.
    Crosasso, P.
    De Iaco, F.
    Di Perri, G.
    Eandi, M.
    Fenoglio, R.
    Giusti, M.
    Imperiale, D.
    Imperiale, G.
    Livigni, S.
    Manno, E.
    Massara, C.
    Milone, V.
    Natale, G.
    Navarra, M.
    Oddone, V.
    Osella, S.
    Piccioni, P.
    Radin, M.
    Roccatello, D.
    Rossi, D.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (03) : 529 - 532
  • [47] Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin
    Kelly, Mary
    O'Connor, Roisin
    Townsend, Liam
    Coghlan, Miriam
    Relihan, Eileen
    Moriarty, Miriam
    Carr, Bernard
    Melanophy, Gail
    Doyle, Caitriona
    Bannan, Ciaran
    O'Riordan, Ruth
    Merry, Concepta
    Clarke, Susie
    Bergin, Colm
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (03) : 1150 - 1154
  • [48] COVID-19 and off label use of drugs: an ethical viewpoint
    Shojaei, Amirahmad
    Salari, Pooneh
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 28 (02) : 789 - 793
  • [49] COVID-19 and off label use of drugs: an ethical viewpoint
    Amirahmad Shojaei
    Pooneh Salari
    DARU Journal of Pharmaceutical Sciences, 2020, 28 : 789 - 793
  • [50] Multiple drugsSevere COVID-19, prolonged viral shedding, lack of efficacy and off-label use: case report
    Reactions Weekly, 2022, 1903 (1) : 275 - 275
12345